Article Information
History
- March 26, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- David W Eyre1,2,3,4,*,
- Sheila F Lumley1,3,4,5,
- Jia Wei5,
- Stuart Cox1,
- Tim James1,
- Anita Justice1,
- Gerald Jesuthasan1,
- Denise O’Donnell5,
- Alison Howarth5,
- Stephanie B Hatch5,
- Brian D Marsden5,6,
- E Yvonne Jones5,
- David I Stuart5,
- Daniel Ebner5,7,
- Sarah Hoosdally3,4,5,
- Derrick W Crook1,3,4,5,
- Tim EA Peto1,3,4,5,
- Timothy M Walker5,8,
- Nicole E Stoesser1,3,4,5,
- Philippa C Matthews1,3,4,5,
- Koen B Pouwels2,4,
- A Sarah Walker3,4,5 and
- Katie Jeffery1
- 1Oxford University Hospitals NHS Foundation Trust, Oxford, UK
- 2Nuffield Department of Population Health, University of Oxford, Oxford, UK
- 3NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
- 4NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at University of Oxford in partnership with Public Health England, Oxford, UK
- 5Nuffield Department of Medicine, University of Oxford, Oxford, UK
- 6Kennedy Institute of Rheumatology Research, University of Oxford, UK
- 7Target Discovery Institute, University of Oxford, Oxford, UK
- 8Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam
- ↵*Corresponding author:
David Eyre, david.eyre{at}bdi.ox.ac.uk, +44 (0)1865 221081, Microbiology Department, John Radcliffe Hospital, Headley Way, Oxford, OX3 9DU
Posted March 26, 2021.
Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status
